title: Impact of statins and beta-blocker therapy on mortality after coronary artery bypass graft surgery.
abstract: BACKGROUND
  We conducted a retrospective cohort study of patients after first-time isolated coronary artery bypass graft surgery (CABG) and assessed the impact of a discharge regimen including beta-blockers and statin therapy and their relationship to long-term all cause mortality and major adverse cardiovascular events (MACE).
  
  
  METHODS
  We identified patients age >18 years, undergoing first time isolated CABG from 1993 to 2005. Patients were identified using the Cardiovascular Information Registry (CVIR). We collected follow-up information at 30, 60, 90 days and yearly follow-up. The registry is approved for use in research by the institutional review broad.
  
  
  RESULTS
  We identified 5,205 patients who underwent single isolated CABG between January 1993 and December 2005. The mean age was 64.5±9.7 years and over 70% were male. There was a significant difference in the low density lipoproteins (LDL) concentration between those with or without statin medications (134±41.9 mg/dL) (no statin) vs. 126±44.8 mg/dL (with statin), P=0.001. A discharge regimen with statin therapy was associated with and overall reduction in 30 day, 1 year and long-term mortality. In addition, overall the triple ischemic endpoint of death, myocardial infarction (MI) and stroke was also significantly lower in the statin vs. no-statin group. In addition, statin and beta-blockers exerted synergistic effect on overall mortality outcomes short-term and in the long-term. We note that the predictors of overall death include no therapy with statin therapy and age [hazard ratios (HR) 1.1, 95% CI: 1.04-1.078, P<0.001] and presence of renal failure (HR 2.0, P=0.005). The estimated 11-year Kaplan Meier curves for mortality between the two groups starts to diverge immediately post discharge after single isolated CABG and continue to diverge through out the follow-up period.
  
  
  CONCLUSIONS
  A post-discharge regimen of statins independently reduces overall and 1 year mortality. These results confirm those of earlier studies within a contemporary surgical population and support the current clinical guidelines.
authors.affiliation: 1 Department of Cardiovascular Medicine, UC Davis Medical Center, Sacramento, California, USA ; 2 Department of Cardiovascular Medicine and Cardiothoracic Surgery, Heart and Vascular Institute, Cleveland Clinic, Cleveland, USA.
authors.forename: Femi
authors.initials: F
authors.lastname: Philip
authors.affiliation: 1 Department of Cardiovascular Medicine, UC Davis Medical Center, Sacramento, California, USA ; 2 Department of Cardiovascular Medicine and Cardiothoracic Surgery, Heart and Vascular Institute, Cleveland Clinic, Cleveland, USA.
authors.forename: Eugene
authors.initials: E
authors.lastname: Blackstone
authors.affiliation: 1 Department of Cardiovascular Medicine, UC Davis Medical Center, Sacramento, California, USA ; 2 Department of Cardiovascular Medicine and Cardiothoracic Surgery, Heart and Vascular Institute, Cleveland Clinic, Cleveland, USA.
authors.forename: Samir R
authors.initials: SR
authors.lastname: Kapadia
keywords: Statin; beta-blocker; coronary artery bypass grafting (CABG)